Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars : Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis

Show full item record



Permalink

http://hdl.handle.net/10138/307590

Citation

Lindström , U , Glintborg , B , Di Giuseppe , D , Nordström , D , Provan , S A , Gudbjornsson , B , Askling , J , Hetland , M L , Aaltonen , K , Krogh , N S , Geirsson , A J & Jacobsson , L T H 2019 , ' Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars : Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis ' , RMD open , vol. 5 , no. 2 , 001079 . https://doi.org/10.1136/rmdopen-2019-001079

Title: Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars : Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis
Author: Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Nordström, Dan; Provan, Sella Aarrestad; Gudbjornsson, Bjorn; Askling, Johan; Hetland, Merete Lund; Aaltonen, Kalle; Krogh, Niels Steen; Geirsson, Arni Jon; Jacobsson, Lennart T. H.
Other contributor: University of Helsinki, HUS Internal Medicine and Rehabilitation



Date: 2019-06
Language: eng
Number of pages: 8
Belongs to series: RMD open
ISSN: 2056-5933
DOI: https://doi.org/10.1136/rmdopen-2019-001079
URI: http://hdl.handle.net/10138/307590
Abstract: Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naive patients with spondyloarthritis (SpA) are lacking. The objectives were to compare treatment retention in biologics-naive patients with SpA starting either the originator product or a biosimilar of infliximab and etanercept, and to explore the baseline characteristics of these patients. Methods Patients with SpA (ankylosing spondylitis/non-radiographical axial SpA/undifferentiated SpA), starting infliximab or etanercept as their first-ever biological disease-modifying antirheumatic drug during January 2014-June 2017 were identified in five Nordic biologics-rheumatology registers. Baseline characteristics were retrieved from each registry; comorbidity data were identified through linkage to national health registers. Country-specific data were pooled, and data on infliximab and etanercept were analysed separately. Comparisons of treatment retention between originators and biosimilars were assessed through survival probability curves, retention rates (2 years for infliximab/1 year for etanercept) and Hazard Ratios (HR). Results We included 1319 patients starting infliximab (24% originator/76% biosimilar), and 1015 patients starting etanercept (49% originator/51% biosimilar). Baseline characteristics were largely similar for the patients treated with the originators compared with the corresponding biosimilars. Survival probability curves were highly similar for the originator and its biosimilar, as were retention rates: infliximab 2-year retention originator, 44% (95% CI 38% to 50%)/biosimilar, 46% (95% CI: 42% to 51%); and etanercept 1-year retention originator, 66% (95% CI 61% to 70%)/biosimilar, 73% (95% CI 68% to 78%). HRs were not statistically significant. Conclusion This observational study of biologics-naive patients with SpA from five Nordic countries showed similar baseline characteristics and very similar retention rates in patients treated with originators versus biosimilars, for both infliximab and etanercept, indicating comparable effectiveness in clinical practice.
Subject: DOUBLE-BLIND
INNOVATOR INFLIXIMAB
PARALLEL-GROUP
CT-P13
SAFETY
ARTHRITIS
EFFICACY
SWITCH
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
e001079.full.pdf 431.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record